NewEdge Advisors’s Anika Therapeutics ANIK Stock Holding History

NewEdge Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,492	Closed	-$139K	–	4138
2025 Q4	$139K	Buy	+14,492	New	+$139K	﹤0.01%	2681

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NewEdge Advisors's ANIK Position: Q1 2026 in Review

NewEdge Advisors sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 14,492 shares — an estimated $139K sold.

NewEdge Advisors first reported a position in ANIK in Q4 2025 and held it in 1 quarter. The position peaked at $139K in Q4 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

NewEdge Advisors reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 14,492 Anika Therapeutics shares in Q1 2026, an estimated $139K.
NewEdge Advisors first reported a position in Anika Therapeutics in Q4 2025 and held it in 1 quarter.
NewEdge Advisors's Anika Therapeutics position peaked at $139K in Q4 2025.
130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.